Akti-1/2, an allosteric inhibitor of Akt 1 and 2, efficiently inhibits CaMKIα activity and aryl hydrocarbon receptor pathway.

@article{Gilot2010Akti12AA,
  title={Akti-1/2, an allosteric inhibitor of Akt 1 and 2, efficiently inhibits CaMKIα activity and aryl hydrocarbon receptor pathway.},
  author={David Gilot and Fanny Giudicelli and Dominique Lagadic-Gossmann and Olivier Fardel},
  journal={Chemico-biological interactions},
  year={2010},
  volume={188 3},
  pages={546-52}
}
Deregulation of the phosphatidylinositol 3 (PI3) kinase/Akt pathway, resulting in enhanced Akt activity, is one of the most frequent changes in human cancer. Akt has therefore attracted significant attention as an anticancer target in recent years and many Akt inhibitors have been identified, especially Akti-1/2, a non-ATP competitive inhibitor of Akt isoforms 1 and 2. In this study, our results suggest that caution may be required when using Akti-1/2 as a specific inhibitor of Akt since it… CONTINUE READING

Similar Papers

Loading similar papers…